A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published in the 12 February 2015 issue of Cell [I.F:33] by Drs. Alberto Mantovani , Eduardo Bonavita and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: AntagomiR-based therapy for cancer: MiRNA-224 suppresses the expression of oncogenic suppressor PTX3 and promotes complement-dependent inflammation and cancer. This study suggests, for the first time, that MiRNA-224, by suppresing the expression of its target gene, it may promote: (1) complement-dependent tumor inflammation, and (2) tumorigenesis. Together, pharmacological formulations encompassing “MiRNA-224 inhibitors” may be used to treat patients suffering from inflammation-associated tumorigenesis.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, AntagomiR-based therapy for cancer: MiRNA-224 suppresses the expression of oncogenic suppressor PTX3 and promotes complement-dependent inflammation and cancer, 25/February/2015, 19.41, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Amount: $500*
